ArticleCurrent pharmaceutical biotechnology2026
Genetic Evidence for Causal Effects of Lipid-lowering Drug Targets on Primary Sjögren's Syndrome Risk: A Mendelian Randomization Study.
Yuying Li et al.PubMed ↗Publisher ↗
No numbers read from the abstract.